[PRNewswire] Invivoscribe Announces FDA Approval of the LeukoStrat CDx FLT3
전체 맥락을 이해하기 위해서는 본문 보기를 권장합니다.
"FDA approval of the LeukoStrat CDx FLT3 Mutation Assay as a companion diagnostic to VANFLYTA is a significant milestone for patients with newly diagnosed FLT3-ITD positive AML," said Invivoscribe CSO, CEO, and founder Jeffrey Miller. "Timely and accurate testing for FLT3-ITD mutations in newly diagnosed patients is critical to identify those who may be eligible for treatment with VANFLYTA, and we are happy to collaborate with Daiichi Sankyo to help bring this important new therapy to patients."
이 보도자료는 자료 제공사에서 제공한 것으로, 연합뉴스는 내용에 대해 어떠한 편집도 하지 않았으며, 연합뉴스의 편집방향과는 무관함을 밝혀 드립니다.
이 글자크기로 변경됩니다.
(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.
Mutation Assay to Select Patients with FLT3-ITD Positive AML for Treatment with VANFLYTA
(SAN DIEGO, July 21, 2023 PRNewswire=연합뉴스) Invivoscribe is excited to announce that the LeukoStrat(R) CDx FLT3 Mutation Assay has been approved by the U.S. Food and Drug Administration (FDA) to aid in the selection of patients with newly diagnosed FLT3-ITD positive acute myeloid leukemia (AML) who may be eligible to receive treatment with Daiichi Sankyo's VANFLYTA(R) (quizartinib).
The LeukoStrat CDx FLT3 Mutation Assay identifies FLT3-ITD positive AML patients who may be treated with this newly approved targeted therapy.
US Intended Use
The LeukoStrat CDx FLT3 Mutation Assay is a PCR-based in vitro diagnostic test designed to detect internal tandem duplication (ITD) and tyrosine kinase domain (TKD) mutations D835 and I836 in the FLT3 gene in genomic DNA extracted from mononuclear cells obtained from peripheral blood or bone marrow aspirates of patients diagnosed with acute myelogenous leukemia (AML).
The LeukoStrat CDx FLT3 Mutation Assay is used as an aid in the assessment of patients with AML for whom RYDAPT(R) (midostaurin) treatment is being considered.
The LeukoStrat CDx FLT3 Mutation Assay is used as an aid in the assessment of patients with AML for whom XOSPATA(R) (gilteritinib) treatment is being considered.
The LeukoStrat CDx FLT3 Mutation Assay is used as an aid in the assessment of patients with FLT3-ITD+ AML for whom VANFLYTA(R) (quizartinib) treatment is being considered.
The test is for use on the 3500xL Dx Genetic Analyzer.
"FDA approval of the LeukoStrat CDx FLT3 Mutation Assay as a companion diagnostic to VANFLYTA is a significant milestone for patients with newly diagnosed FLT3-ITD positive AML," said Invivoscribe CSO, CEO, and founder Jeffrey Miller. "Timely and accurate testing for FLT3-ITD mutations in newly diagnosed patients is critical to identify those who may be eligible for treatment with VANFLYTA, and we are happy to collaborate with Daiichi Sankyo to help bring this important new therapy to patients."
AML is a blood cancer that affects the blood and bone marrow and is characterized by the rapid growth of abnormal white blood cells.[1] AML has the lowest 5-year survival rate (31.7%) among people diagnosed with leukemia.[2] About 25% of AML patients have a FLT3-ITD mutation which contributes to the growth and survival of cancer cells and is associated with a poor prognosis.[3]
Previously, the LeukoStrat CDx FLT3 Mutation Assay was approved by the Japan Pharmaceuticals and Medical Devices Agency (PMDA) for use as a companion diagnostic to select FLT3-ITD positive AML patients eligible for VANFLYTA in Japan.
About Invivoscribe
Invivoscribe is a global, vertically-integrated biotechnology company dedicated to Improving Lives with Precision Diagnostics(R). For nearly thirty years, Invivoscribe has improved the quality of healthcare worldwide by providing high quality standardized reagents, tests, and bioinformatics tools to advance the field of precision medicine. Invivoscribe has a successful track record of partnerships with global pharmaceutical companies interested in developing and commercializing companion diagnostics, and provides expertise in both regulatory and laboratory services. Providing distributable kits, as well as clinical trial services through its globally located clinical lab subsidiaries (LabPMM), Invivoscribe is an ideal partner from diagnostic development, through clinical trials, regulatory submissions, and commercialization. For additional information, please visit www.invivoscribe.com or contact us at inquiry@invivoscribe.com and follow us on LinkedIn [https://www.linkedin.com/company/invivoscribe/ ].
[1] https://www.cancer.net/cancer-types/leukemia-acute-myeloid-aml/introduction
[2] https://seer.cancer.gov/statfacts/html/amyl.html
[3] Daver N et al. Leukemia (2019) 33:299-312.
Logo - https://mma.prnewswire.com/media/1019746/Invivoscribe_Logo.jpg
Invivoscribe 2019 Logo
Source: Invivoscribe, Inc.
[편집자 주] 이 보도자료는 자료 제공사에서 제공한 것으로, 연합뉴스는 내용에 대해 어떠한 편집도 하지 않았으며, 연합뉴스의 편집방향과는 무관함을 밝혀 드립니다.
(끝)
출처 : PRNewswire 보도자료
Copyright © 연합뉴스 보도자료. 무단전재 및 재배포 금지.
- [2보] 日 차기 총리에 '한일 역사인식 비둘기파' 이시바 시게루 | 연합뉴스
- 의료개혁에 30조원 투입…중증수술·치료 수가 대폭 올린다(종합) | 연합뉴스
- aT "배추 평균 소매가 9천963원"…2년 만에 1만원 넘나 | 연합뉴스
- 경찰, '이재명 무료변론' 사건 불송치…청탁금지법 위반 무혐의 | 연합뉴스
- '불법 선거운동' 최재영 목사 경찰 출석…"대통령도 수사하라"(종합) | 연합뉴스
- 한일, '7광구' 개발회의 39년만에 개최…"폭넓은 논의, 협의 지속" | 연합뉴스
- '음주운전 추적 중계' 사망사고 연루 유튜버 불구속 입건 | 연합뉴스
- 당정, 농업인 지원금 상향…공익직불제 예산 3.4조원으로 확대(종합) | 연합뉴스
- 의대에 뺏길라…과학기술인재 어릴때부터 키우고, 정년연장 검토 | 연합뉴스
- 전운 고조에…서방, 전면전시 레바논서 자국민 피란 방안 검토 | 연합뉴스